Despite getting criticized for admitting an error in tests for its coronavirus disease 2019 (Covid-19) vaccine, UK-based AstraZeneca is pushing the conduct of a Phase 3 clinical trial in the Philippines, an official of the Department of Science and Technology (DOST) said on Monday.
In a virtual presser, DOST-Philippine Council for Health Research and Development Executive Director Jaime Montoya said AstraZeneca already signed the Confidentiality Disclosure Agreement that would allow the Philippines’ Vaccine Expert Panel (VEP) to check the data on the firm’s Phase 1 and 2 clinical trials for its Covid-19 vaccine.
Upon checking the data, the VEP would then recommend to the Ethics Review Committee and the Food and Drug Administration (FDA) the conduct of the clinical trial in the country.
“For now, the VEP is basing its evaluation from the documents that AstraZeneca initially submitted,” Montoya said.
He said the VEP has completed its initial evaluation and sent questions to AstraZeneca.”If they could answer all those questions, then the VEP could recommend the conduct of the clinical trial to the Ethics Review Committee, and the FDA which has the final decision on whether the clinical trial can be done here or not,” he said. SOVEREIGNPH